CA
NZ
UK
AU
IND
US
ResMed rallied on above-average volume after Morgans reiterated its Buy at A$41.72, citing the 16x forward earnings valuation as the lowest since the post-GFC era despite consensus double-digit EPS growth forecasts. Q4 FY2026 earnings on August 6 provide a near-term catalyst checkpoint.Key HighlightsPost-GFC Low …
Recursion Pharmaceuticals advanced as AI-driven drug discovery pipeline progress provided evidence the computational approach generates candidates at scale validating the platform premise. The Bayer strategic partnership provides capital and commercial validation from one of the world's largest pharmaceutical companies.Key HighlightsAI Drug Discovery Pipeline Validation:Progress …
The Logistics Problem That NV-387 Solves
The Historical Context: Why MSS CRC Was Considered Immunotherapy-Resistant
When Life Science Tools Companies Trade Below Cash
The Hereditary Angioedema Market and Deucrictibant's Commercial Opportunity
Schizophrenia: The Commercial Opportunity If the Hypothesis Is Correct
Acromegaly: A High-Value Rare Disease With an Established Treatment Paradigm
The Psoriasis Market and Why Differentiation Still Matters
The Anatomy of a Biotech Sell-the-News Event
Please wait processing your request...